Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ikervis in the Treatment of Atopic Keratoconjunctivitis
2022-500633-92-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Dec 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclosporine in atopic keratoconjunctivitis (AKC) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Bulbar Redness score change. Planned start Dec 2023; status: authorised.
02
Drugs
cyclosporine
03
Conditions
atopic keratoconjunctivitis (AKC)
Beyond the preview
Go deeper on 2022-500633-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500633-92-00.